Brett is currently a formulation consultant and has over 35 years industrial experience in transdermal and oral drug delivery resulting in over a dozen products. Dr. Berner is former CSO of Depomed, VP of Development at Cygnus and Director of Pharmaceutics Research at Ciba-Geigy (now Novartis).
After receiving his PhD in Neurosciences/Physical Chemistry from UCLA, he joined Procter & Gamble as a staff scientist working on novel product research on skin. He is also inventor for over 50 pharmaceutical US patents, editor of 2 books, and author of over 80 journal publications on drug delivery.
David is Professor of Anesthesiology and Vice Chair of Research for the Department of Anesthesiology at Stanford University.
Dr. Clark is an active member of American Society of Anesthesiologists, International Anesthesia Research Society, International Association for the Study of Pain, American Pain Society, and Association of University Anesthesiologists.
Dr. Clark is an Editor of the journal Anesthesiology and reviewer for many other scientific journals including Anesthesia and Analgesia; Neuroscience; Nitric Oxide: Biology and Chemistry, The Journal of Pain; Pain, Pharmacology, Biochemistry and Behavior; Free Radical Biology and Medicine; Synapse, and Life Sciences. Dr. Clark received his BA from Carleton College and received his MD and PhD in Pharmacology from Vanderbilt University.
Gendreau has more than 25 years of experience serving as the Chief Medical Officer for both private and public biotechnology companies involved in diagnostics, pharmaceuticals, and medical devices.
His areas of expertise are rheumatology, functional somatic syndromes, chronic and acute pain, schizophrenia, depression, anxiety, and cognition disorders.
Dr. Gendreau was a founding member and Chief Medical Officer of Cypress Bioscience, Inc. He received a BS in Chemistry from Ohio University and MD and PhD degrees in Pharmacology from The Ohio State University.
Stephen is a clinical pharmacology consultant. He has worked at Johnson & Johnson/Alza, Inhale Therapeutics, ALZA Corporation, and Merck & Co.
He has participated in the filing of Testoderm, Nicoderm and Duragesics.
Dr. Hwang holds a PhD in Pharmaceutical Chemistry and a master degree (Chemistry) from University of Michigan, Ann Arbor. He obtained his BS degree from Tsing Hua University (Taiwan).
Kenneth is a consultant and professional manager of medical/scientific enterprises in the areas of pharmaceutical development, clinical regulatory strategy and planning, clinical research and development, product license & acquisition evaluation, strategic planning, and research personnel assessment and training.
Over the past 40 years, he has held senior clinical research positions at major pharma companies (G.D. Searle, Schering-Plough, Ayerst AHP, Johnson & Johnson), as well as VP, Clinical & Regulatory Affairs at biotech and smaller pharma companies. He received his BS, MD and PhD degrees from the University of Chicago.